Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer
Phase 2
- Conditions
- advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000004227
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
user of EGFR tyrosine kinase inhibitors severe complications or active interstitial lung disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall response rate
- Secondary Outcome Measures
Name Time Method overall survival time, safety,progression-free survival